All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2018; the latest 2022-11-29.
From the record
Cyclerion Therapeutics, Inc.'s filings since 2018 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2022-11-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-2% a year over 6 filed years; profitable in 0 of 6.
From the record
Cyclerion Therapeutics, Inc.'s 6 filed years say what it did: revenue went from $2 million in fiscal 2020 to $2 million in fiscal 2025, down 2% a year; it rose in 2 of 4 years; the deepest fall was 100% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Cyclerion Therapeutics, Inc.'s shareholder treatment is put at 5.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 41% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -39%: lost 39¢ per shareholder dollar. Leverage 9%: owes 9¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Cyclerion Therapeutics, Inc. lost about 39 cents for every dollar of shareholders' money. Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count grew 26.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 46% of 315 in its family; net margin -170.1%.
From the record
Cyclerion Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 29% by size; a net margin of -170.1% ranks in the bottom 48%; revenue growth of 91.1% a year over the last 3 filed years ranks in the top 14% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 40% of 315 in its family for leadership; chief executive since 2024.
From the record
Cyclerion Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Graul, Regina Margaret (President and Chief Executive Officer, as filed), filing under that title since 2024-08-07, 2.3 years (bottom 25% of its family); most of the 12 officers and directors filing now have filed since the record of its people begins (2026-09-10), a floor of 2 months the record cannot see past, so that part is not read; 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 44%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 273 in its family for room to expand.
From the record
Cyclerion Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 32.4% of its assets as net cash, top 45% of its family; cash from operations less capital spending is -159.8% of revenue (bottom 45%); research spending of 46.2% of revenue (bottom 42%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 48% of 306 in its family for growth drivers.
From the record
Cyclerion Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 91.1% a year over the last three filed years against -2% over all 6, speeding up (top 5% of its family); the newest year grew 3.7% (bottom 43%); research spending grew -45.7% a year (bottom 5%) (its annual reports). Cyclerion Therapeutics, Inc. reported 3 product lines in fiscal 2025: License Agreement at $1 million (48%), Purchase Agreement at $800 thousand (39%), Option Agreement at $274 thousand (13%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 38% of 233 in its family for expectations against reality.
From the record
Cyclerion Therapeutics, Inc.'s newest year against its own record: revenue of $2 million in fiscal 2025 came in 60% below the $5 million its prior three years' pace pointed to (bottom 16% of its family); net income of $4 million against a prior three-year average of $17 million (top 22%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 8%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made